How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13761. Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast; Written informed consent; Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from (...) , 2008 Last Update Posted: August 17, 2016 Last Verified: August 2016 Keywords provided by Fondazione Italiana Linfomi ONLUS: MANTLE CELL LYMPHOMA (MCL) Lenalidomide (Len) Dexamethasone (Dex) Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Mantle-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Dexamethasone Dexamethasone acetate Lenalidomide BB 1101

2008 Clinical Trials

13762. Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

that led to HIV-1 acquisition Pregnancy or breastfeeding History of malignancy (other than localized squamous cell or basal cell cancer of the skin) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00781287 Locations Layout table for location (...) of the integrase inhibitor raltegravir (400 mg BID orally) to inhibit the integration step of the HIV-1 life cycle in conjunction with HAART in subjects with recently acquired HIV-1 infection will decrease the number of HIV-1 infected CD4+ T-cells to a greater extent than a 3-drug HAART regimen. Condition or disease Intervention/treatment Phase Human Immunodeficiency Virus Drug: 3-drug anti-HIV therapy Drug: Raltegravir Phase 4 Detailed Description: The study will be conducted at the UW Primary Infection

2008 Clinical Trials

13763. Mesenchymal Stem Cells and Subclinical Rejection

[shingles], cytomegalovirus (CMV), Pneumocystis carinii (PCP), aspergillosis, histoplasmosis, or mycobacteria other than TB) after transplantation. Malignancy (including lymphoproliferative disease) within the past 2-5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence) according to current transplantation inclusion criteria. Known recent substance abuse (drug or alcohol). Contraindications to undergo a BM biopsy. Contacts and Locations Go (...) Details Study Description Go to Brief Summary: The purpose of the study is to test the safety and feasibility of autologous mesenchymal stem cell therapy in HLA-DR mismatched patients with subclinical rejection and or an increase in IF?TA in the renal biopsy 4 weeks or 6 months after renal transplantation. Condition or disease Intervention/treatment Phase Organ Transplantation Procedure: Mesenchymal stem cell infusion Phase 1 Phase 2 Detailed Description: Kidney transplantation has improved survival

2008 Clinical Trials

13764. Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

investigational drug therapy within 30 days of study entry Secondary leukemia or history of antecedent hematologic disorder History of second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for three or more years) No active CNS disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma Concomitant anticoagulant therapy is not permitted (with the exception of 1 mg/day (...) , 2018 Last Verified: August 2018 Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Cyclophosphamide Rituximab Doxorubicin Prednisone Vincristine Liposomal doxorubicin Oblimersen Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic

2008 Clinical Trials

13765. Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

for randomization, unless the second cancer was treated only with surgical removal (e.g., basal, squamous or localized melanoma skin cancer, or breast ductal carcinoma in situ [DCIS]) These survivors will, however, have full access to the website if they have completed the required baseline assessment; they will be asked to also complete follow-up assessments Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study (...) Negative Blastic Phase Chronic Myelogenous Leukemia Cancer Survivor Chronic Eosinophilic Leukemia Chronic Myelomonocytic Leukemia Chronic Neutrophilic Leukemia Chronic Phase Chronic Myelogenous Leukemia de Novo Myelodysplastic Syndromes Depression Disseminated Neuroblastoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Fatigue Long-term Effects Secondary to Cancer Therapy in Adults Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Nodal Marginal Zone B-cell

2008 Clinical Trials

13766. Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

to interfere with participation in this clinical study Cardiac or pulmonary dysfunction such that patients do not meet institutional pre-transplant evaluation criteria Known central nervous system involvement or suspicion of involvement with Myeloma Other active malignancies (with the exception of basal and squamous cell skin cancer) within 5 years of study entry. Patients with treated prostate or cervical cancer in situ who are 2 or more years from therapy and remain free of disease may be entered (...) , 2012 Last Update Posted: August 30, 2012 Last Verified: August 2012 Keywords provided by Sagar Lonial, Emory University: Cancer Multiple Myeloma Peripheral Blood Stem Cell Transplant Additional relevant MeSH terms: Layout table for MeSH terms Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders

2008 Clinical Trials

13767. Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

investigator; patients with underlying cardiopulmonary dysfunction should be excluded from the study Patients must have Zubrod performance status of 0-2 No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years Collection and submission of pre (...) and help destroy any remaining cancer cells (graft-versus-tumor effect). Condition or disease Intervention/treatment Phase Acute Lymphoblastic Leukemia Adult Acute Lymphoblastic Leukemia in Remission Adult B Acute Lymphoblastic Leukemia Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Adult L1 Acute Lymphoblastic Leukemia Adult L2 Acute Lymphoblastic Leukemia Adult T Acute Lymphoblastic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic

2008 Clinical Trials

13768. Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma

should be done if available at some time in the patient's course before this therapy) Radiologic staging studies may be performed up to 6 weeks prior to starting therapy and not be repeated if the treating physician feels it unnecessary No other prior malignancy is permitted except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for one year. Age > or = to 18 years of age For patients who are in first (...) information Responsible Party: Duke University ClinicalTrials.gov Identifier: Other Study ID Numbers: 2165 First Posted: January 4, 2008 Last Update Posted: July 18, 2014 Last Verified: July 2014 Keywords provided by Duke University: Intensive Induction High Dose Chemotherapy Bone Marrow Transplantation Mantle Cell Lymphoma Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Mantle-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases

2007 Clinical Trials

13769. A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

1 Other invasive malignancies within 3 years prior to Day 1 except for adequately treated basal cell or squamous cell skin cancer, in situ carcinoma of the cervix, in situ breast cancer, in situ prostate cancer, or other cancer of which the patient has been disease-free for at least 3 years History or evidence on physical examination of CNS disease Active infection requiring parenteral antibiotics within 14 days of Day 1 Major surgical procedure (excluding lymph node biopsy) or significant (...) zone NHL At least one previous treatment with rituxan monotherapy or a rituximab-containing regimen Measurable disease Either fresh or archived tumor specimen must be available for central confirmation of diagnosis and correlative studies Life expectancy of > 3 months For patients of reproductive potential, use of a reliable means of contraception Exclusion Criteria: Chemotherapy or radiotherapy within 28 days of Day 1 Prior treatment with a monoclonal antibody directed against CD40

2007 Clinical Trials

13770. Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

mg/dL or creatinine clearance of 20 ml/min or less Other uncontrolled disease that could prevent safe study completion History of any malignant neoplasm except adequately treated basal or squamous cell carcinoma of the skin or solid tumors treated with curative therapy and disease-free for at least 5 years Receipt of an investigational agent or device within 30 days prior to study entry A live vaccination within 4 weeks prior to study entry Presence of a positive tuberculin skin test (...) : National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Collaborators: The Cleveland Clinic Office of Rare Diseases (ORD) Rare Diseases Clinical Research Network Information provided by (Responsible Party): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Study Details Study Description Go to Brief Summary: Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms

2007 Clinical Trials

13771. Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Untreated, biopsy proven B-cell non-Hodgkin's lymphoma Age >/= 18 years No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for one year. The patient cannot have been exposed (...) nodules must regress by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter. Except splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. Patients who achieve a CR by the above criteria, but who have persistent morphologic bone marrow involvement will be considered partial responders. No new sites of disease should be observed. Secondary Malignancies [ Time Frame: 10 years ] The number of patients who

2007 Clinical Trials

13772. Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. Positive HIV antibody Prior malignancies except for adequately treated basal cell or squamous cell carcinoma of the skin Hepatitis B surface antigen positivity Prior bone marrow transplantation PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior bone marrow transplantation Contacts and Locations Go to Information from the National (...) diffuse large cell lymphoma stage III adult Burkitt lymphoma stage IV adult Burkitt lymphoma Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Non-Hodgkin Lymphoma, Mantle-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Cyclophosphamide Carmustine Etoposide Etoposide phosphate Sargramostim Lenograstim Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs

2007 Clinical Trials

13773. R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas

Index) score 2 or 3 ECOG performance status 0-3 signed informed consent Exclusion criteria were: relapsed lymphoma previous treatment (up to one cycle of standard pretreatment - COP, CHOP or steroids was permitted and later became mandatory to decrease disease burden and/or improve the performance status of the patient) Burkitt lymphoma posttransplant lymphoproliferation CNS involvement other malignant tumor in previous history, except basalioma, skin squamocellular carcinoma or cervical carcinoma (...) permitted and latter mandatory to decrease tumor burden and/or improve performance status) Other tumor in previous history with the exception of basalioma, squamous cell carcinoma of the skin or cervical carcinoma in situ Pregnancy/lactation CNS involvement Other serious comorbidities Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor

2007 Clinical Trials

13774. Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma

treated basal cell or squamous cell skin cancers, carcinoma in situ of the cervix, or any other cancer from which the patient has been disease free for > 5 years are allowed) Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to the first drug intake Any acute or chronic medical condition, which could impair the ability of the patient to participate to the study or could interfere with interpretation of study results Uncontrolled (...) : All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients with non-Hodgkin B-cell lymphoma, good condition, not previously treated Exclusion Criteria: Contraindication to any drug contained in the R-CHOP (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate) Less than 42 days elapsed from prior major surgery (28 days from other prior surgery) to the time of inclusion Cerebral or leptomeningeal involvement. History of another neoplasm (Adequately

2008 Clinical Trials

13775. Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

cytogenetics predictive of secondary cancers, such as -5,-7. Pregnant (Positive Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women. Patients with other malignancies diagnosed within 2 years prior to Study entry (except skin squamous or basal cell carcinoma). Active uncontrolled bacterial, viral fungal (...) : No Keywords provided by M.D. Anderson Cancer Center: Diffuse Large Cell Lymphoma Lymphoma Zevalin Ibritumomab IDEC-Y2B8 Carmustine BCNU BiCNU Etoposide VePesid Cytarabine Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Melphalan Rituximab Rituxan BEAM Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases

2007 Clinical Trials

13776. The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus

Tuberculosis) Negative screen for Epstein-Barr Virus (EBV) or by an EBNA method Invasive aspergillus infection within a year prior to study entry Any history of malignancy except for adequately treated squamous cell or basal cell carcinoma of the skin Active alcohol or substance abuse which includes cigarette smoking (must be abstinent for 6 months). Active alcohol use abuse should be considered using the current NIAAA definitions whereby alcohol abuse is defined by a pattern of drinking (...) patients with a history of severe hypoglycemia and/or hypoglycemia unawareness who have been selected for pancreatic islet cell allotransplantation; (2) T1DM patients who also have a history of severe hypoglycemia and/or hypoglycemia unawareness; (3) nondiabetic subjects. All subjects will undergo identical testing including: (a) screening; (b) neuropsychological testing; (c) and functional magnetic resonance imaging (fMRI) during euglycemic and hypoglycemic conditions. Condition or disease Diabetes

2007 Clinical Trials

13777. Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

or creatinine clearance ≥ 60 mL/min FEV_1 > 65% of predicted or DLCO ≥ 50% of predicted LVEF > 50% by ECHO or MUGA scan Bilirubin ≤ 1.5 times normal SGOT or SGPT ≤ 2 times normal HIV antibody-negative No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinoma, or other cancer from which the patient has been disease-free for at least five years No active evidence of hepatitis B or C infection No hepatitis B surface antigen positivity (...) for details. ClinicalTrials.gov Identifier: NCT00562978 Recruitment Status : Completed First Posted : November 26, 2007 Last Update Posted : June 1, 2018 Sponsor: City of Hope Medical Center Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): City of Hope Medical Center Study Details Study Description Go to Brief Summary: RATIONALE: Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry tumor-killing substances

2007 Clinical Trials

13778. Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

, C, DRB1 allele level matched unrelated marrow donor or 4/6 HLA-A, B (antigen level), DRB1 (allele level) matched unrelated cord blood donor (fourth priority) Exclusion criteria: Active infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days) Squamous cell carcinoma of the skin History of human immunodeficiency virus (HIV) infection Prior transplantation with donor skin Contacts and Locations Go to Information from the National Library (...) , University of Minnesota Information provided by (Responsible Party): Masonic Cancer Center, University of Minnesota Study Details Study Description Go to Brief Summary: RATIONALE: In animal models, stem cells have been shown to home to the skin and repair the biochemical and structural abnormalities associated with recessive dystrophic epidermolysis bullosa (RDEB) (collagen 7 deficiency). PURPOSE: To determine the safety and effectiveness of stem cell infusion in the treatment of RDEB. Condition

2007 Clinical Trials

13779. A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

. Exclusion Criteria: known hypersensitivity reaction to rituximab, or known anti-murine antibody reactivity or known hypersensitivity to murine antibodies; active malignancy other than mantle cell lymphoma within 5 years of start of study, with the exception of resected basal cell cancer, squamous cell cancer of the skin, or in situ cancer of the cervix; serious disorders interfering with full standard dosing chemotherapy; stage I disease. Contacts and Locations Go to Information from the National (...) Hoffmann-La Roche More Information Go to Layout table for additonal information Responsible Party: Hoffmann-La Roche ClinicalTrials.gov Identifier: Other Study ID Numbers: ML20493 First Posted: May 11, 2007 Results First Posted: November 26, 2014 Last Update Posted: August 15, 2017 Last Verified: June 2017 Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Mantle-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative

2007 Clinical Trials

13780. Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

prednisone greater than 20 mg/d within past month short-bowel syndrome total parenteral nutrition abnormal liver function malignancy active within past 5 years (except completely resected basal or squamous cell carcinoma of skin) enteric pathogens, including C. difficile history of colonic mucosal dysplasia current or prior evidence of TB (unless risk of activation or re-activation deemed low) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study (...) Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>